BCL2 and B-cell non-Hodgkin lymphoma: Preclinical and early clinical studies demonstrated that ABT-199 inhibits the growth of aggressive c-MYC-driven mouse B-cell lymphomas and human BCL2-dependent B-cell lymphoma tumors in vivo without causing thrombocytopenia [375, 377].